Neyrokson

General characteristics. Structure:

Active ingredient: citicoline;
1 ampoule contains a tsitikolin of sodium, in terms of цитиколин 500 mg or 1000 mg;
excipients: water for injections.

Pharmacological properties:

Pharmacodynamics. Tsitikolin stimulates biosynthesis of structural phospholipids in a membrane of neurons that promotes improvement of functions of membranes, including functioning of ion-exchange
pumps and neuroceptors. Thanks to the stabilizing action on a membrane цитиколин has antiedematous properties therefore reduces wet brain. Tsitikolin oppresses activity of some phospholipases, interferes with residual release of free radicals, prevents damage of membrane systems and provides preservation of protective antioxidant system. Tsitikolin reduces the volume of the damaged fabric, preventing death of cells, affecting apoptosis mechanisms, and improves cholinergic transfer. Tsitikolin also has preventive neurotyre-tread effect at focal strokes of a brain. Tsitikolin promotes bystry functional rehabilitation of patients at acute disorders of cerebral circulation, reducing ischemic defeat of tissues of brain that is confirmed by results of X-ray inspections. At craniocereberal injuries цитиколин reduces duration of the recovery period and reduces intensity of a posttraumatic syndrome. Tsitikolin promotes increase in level of brain activity, reduces amnesia level, improves a state at cognitive, sensitive and motor disturbances which are observed at brain ischemia.

Pharmacokinetics. Tsitikolin is well soaked up at peroral, intramuscular and intravenous administration. After administration of drug substantial increase of level of sincalines in a blood plasma is observed. At oral administration drug is almost completely soaked up. Showed researches that
bioavailability at peroral and parenteral ways of introduction are almost identical. Drug is metabolized in intestines and a liver with formation of sincaline and cytidine. Later
introductions цитиколин it is acquired by brain tissues, at the same time sincalines affect phospholipids, cytidine – on cytidine nucleoids and nucleic acids. Tsitikolin quickly reaches tissues of a brain and is actively built in membranes of cells, cytoplasm and mitochondrions, activating activity of phospholipids.
Only the insignificant quantity of the entered dose is removed with urine and a stake (less than 3%). About 12% of the entered dose are removed through respiratory tracts. Removal of drug with urine and through respiratory tracts has two phases: the first phase – bystry removal (with urine – for the first 36 hours, through respiratory tracts – for the first 15 hours), the second phase – slow release. The main part of a dose of drug is involved in metabolism processes.

Main physical and chemical properties: transparent colourless liquid. Incompatibility. It is unknown.

Indications to use:

- Acute phase of disturbances of cerebral circulation and treatment of complications and effects of disturbances of cerebral circulation.
- Craniocereberal injury and its effects.
- The neurologic frustration (cognitive, sensitive, motor) caused by cerebral pathology of degenerative and vascular genesis.

Route of administration and doses:

For intravenous or intramuscular administration.
The recommended dose for adults makes from 500 mg to 2000 mg a day.
Treatment: the first 2 weeks on 500-1000 mg 2 times a day intravenously, then – on 500-1000 mg 2 times a day intramusculary. The maximum daily dose – 2000 mg.
At acute and medical emergencies the maximum therapeutic effect is reached at purpose of drug in the first 24 hours.
In case of need treatment is continued by drug Neyrokson, solution for oral administration. The recommended course of treatment at which the maximum therapeutic effect is observed makes 12 weeks.
Doses of drug and terms of treatment depend on weight of damage of a brain and are established by the doctor individually.
Intravenously appoint in the form of a slow intravenous injection (for 3-5 minutes, depending on the entered dose) or drop intravenous injection (40-60 drops a minute). Patients of advanced age of dose adjustment do not demand. Side reactions.

Features of use:

In case of permanent intracraneal hemorrhage it is not necessary to exceed a dose of 1000 mg a day and speed of intravenous administration of 30 drops a minute. Drug is used right after opening of an ampoule. The ampoule with drug is intended only for single use. The remains of drug need to be destroyed. Ability to influence speed of response at control of motor transport or work with other mechanisms. In some cases some side reactions from the central nervous system can influence ability to manage motor transport and to work with difficult mechanisms.

Side effects:

Side reactions arise very seldom (<1/10000), including isolated cases.
Mental disturbances: hallucinations.
From a nervous system: severe headache, dizziness.
From cardiovascular system: arterial hypertension, arterial hypotension, tachycardia.
From respiratory system: диспноэ.
From a digestive tract: nausea, vomiting, diarrhea.
General disturbances: fever, hypostasis, allergic reactions, including: rash, purpura, itch, Quincke's disease, acute anaphylaxis; fervescence, the increased perspiration, changes in an injection site.

Interaction with other medicines:

Tsitikolin strengthens effect of a levodopa. It is not necessary to appoint along with the medicines containing Meclofenoxatum.

Contraindications:

- Hypersensitivity to drug components.
- The raised tone of a parasympathetic nervous system.

Use during pregnancy or feeding by a breast. There are not enough data on Neyrokson's use to pregnant women. Data on excretion of a tsitikolin in breast milk and its action on a fruit are not known. Therefore during pregnancy or feeding a breast drug is appointed only when the expected advantage for mother exceeds potential risk for a fruit.
Children. There are not enough data on Neyrokson's use to children. Drug is used in urgent cases when the expected advantage of use exceeds potential risk.

Overdose:

Cases of overdose are not described.

Storage conditions:

Period of validity 2 years. To store in the place, unavailable to children, in original packaging at a temperature not above 30 °C.

Issue conditions:

According to the recipe

Packaging:

On 4 ml in an ampoule, on 5 ampoules in the blister, on 2 blisters in a pack.